Literature DB >> 12652224

Cystoid macular degeneration in chronic central serous chorioretinopathy.

Tomohiro Iida1, Lawrence A Yannuzzi, Richard F Spaide, Natalie Borodoker, Cynthia A Carvalho, Silvana Negrao.   

Abstract

PURPOSE: To describe the optical coherence tomography (OCT) and fluorescein angiography findings in the macula of eyes with chronic central serous chorioretinopathy (CSC) and reduced central vision.
METHODS: Using OCT, clinical examination, and fluorescein and indocyanine green (ICG) angiography, the authors examined eight eyes of seven patients with CSC, an attached macula, and reduced central vision of 20/200 or worse. All had a history of chronic CSC with resolution of the subretinal fluid in the macular area and poor vision.
RESULTS: Patient ages ranged from 55 to 82 years (mean, 66 years). All eight eyes had some parafoveal, patchy RPE atrophy with corresponding transmission hyperfluorescence (window defect) on fluorescein angiography. Five eyes also had a window defect in the foveal area. With OCT, the foveal area revealed variable areas of cystoid change and atrophy in seven of the eight eyes. In four of these eyes, the cystoid changes were not seen on clinical examination or fluorescein angiography. The seven eyes with cystoid changes imaged with OCT had no intraretinal leakage of fluorescein in the foveal region. The authors categorized these eyes as having cystoid macular degeneration (CMD). One other eye had foveal thinning or atrophy without cystoid changes.
CONCLUSIONS: Intraretinal cystoid spaces without intraretinal leakage, or CMD, was a common finding in eyes with chronic CSC and reduced central vision after resolution of subretinal fluid. OCT was useful to establish the presence of CMD and foveal atrophy, even when these changes were not clearly evident on clinical examination or fluorescein angiography. Chronic foveal detachment and antecedent intraretinal leakage were proposed to be the mechanisms for the development of the changes. CMD in conjunction with foveal atrophy was an important clinical finding to account for the poor visual outcome in patients with CSC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12652224     DOI: 10.1097/00006982-200302000-00001

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  47 in total

1.  Selective retina therapy in patients with central serous chorioretinopathy.

Authors:  H Elsner; E Pörksen; C Klatt; A Bunse; D Theisen-Kunde; R Brinkmann; R Birngruber; H Laqua; J Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

2.  Optical coherence tomography characterisation of idiopathic central serous chorioretinopathy.

Authors:  J A Montero; J M Ruiz-Moreno
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

Review 3.  Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review.

Authors:  Y-R Chung; E J Seo; H M Lew; K H Lee
Journal:  Eye (Lond)       Date:  2013-11-08       Impact factor: 3.775

4.  Macular cysts, holes and cavitations : 2006 Jules Gonin lecture of the Retina Research Foundation.

Authors:  A Gaudric
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-30       Impact factor: 3.117

5.  Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy.

Authors:  Geoffrey K Broadhead; Andrew Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-12-31       Impact factor: 3.117

6.  Alterations in "in vivo" histology of retina in bilateral chronic central serous chorioretinopathy after intravitreal bevacizumab.

Authors:  Sandeep Saxena; Astha Jain
Journal:  J Ocul Biol Dis Infor       Date:  2012-03-08

7.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

8.  Viagra-associated serous macular detachment.

Authors:  Polly Quiram; Sean Dumars; Bobbie Parwar; David Sarraf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-09       Impact factor: 3.117

9.  One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.

Authors:  Yasuhiro Ohkuma; Takaaki Hayashi; Tsutomu Sakai; Akira Watanabe; Hiroshi Tsuneoka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-02       Impact factor: 3.117

10.  Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.

Authors:  S H Lim; W Chang; M Sagong
Journal:  Eye (Lond)       Date:  2013-03-01       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.